Panthera moves back into recruiting and running commercial oncology clinical trials in the UK

Focus on immunotherapy and hormone therapy

Since announcing that it reopened its oncology clinical trials division earlier this year, Panthera Biopartners has been selected by two of the world’s largest pharma companies to run oncology trials at sites across the UK. Panthera previously had to close its Oncology division as the sites were located inside the four Rutherford Specialist Cancer clinics, which went into administration.

Since then, Panthera has expanded its existing clinical trial sites to recruit for immunotherapy and hormone therapy oncology trials and has recruited a broad team of specialist oncologists PIs.

Chris Dodd, Chief Commercial Officer at Panthera, commented “There is a great shortage of top quality oncology clinical trial sites with experienced oncology specialists across the world. The UK is particularly well placed to become a centre for running commercial oncology trials with top-quality PIs, a diverse population and experienced clinical trial sites. We were very successful in attracting oncology studies to the UK. With our clinics set up to run these trials and a team of world-class oncology specialists, we are well on our way to re-establishing Panthera as a major player in this area.”

Panthera, which has six dedicated clinical trial sites across the UK in Glasgow, York, Sheffield, Preston, Rochdale and Enfield, carries out clinical trials for pharma, biotechs and CROs across a broad range of therapy areas including vaccines, cardiovascular, general medicine, neurology, respiratory and rheumatology.

About Panthera Biopartners

• Panthera is the UK’s largest Site Management Organisation (SMO) that recruits patients and runs clinical trials at six dedicated clinical trial clinics across the UK on behalf of its clients - CROs and pharma.
• The SMO model was originated by Dr Ian Smith MBE – one of the founders of Panthera Biopartners. In 1991 Ian, who was a GP in Chorley, recognised that running clinical trials on a professional basis required a separate organisation that could enrol patients from surrounding GP practices and run the clinics separately so that patients who took part in the trials were not caught up with the patients attending a GP practice. Synexus grew to become the largest SMO in the world with clinics across four continents.
• Since launching in 2019, Panthera has continued to refine the SMO model and has quickly grown to be number one in the UK recruiting patients and running trials on behalf of ten of the top twelve pharmaceutical companies and seven of the top CROs.